← Back to guidelines
Cardiology4 papers

Early-onset Lafora body disease

Last edited: 4/22/2026

Overview

Early-onset Lafora body disease (LBD) is a rare, fatal neurodegenerative disorder characterized by the accumulation of Lafora bodies, which are abnormal aggregates primarily found in neurons and other tissues, leading to progressive myoclonus epilepsy and cognitive decline 2.

Diagnosis

  • Clinical Presentation: Includes myoclonus, epilepsy, and cognitive decline 2.
  • Biopsy Findings: Liver biopsies may show ground-glass hepatocytes with Lafora body-like inclusions, characterized by periodic acid-Schiff (PAS) positivity and ultrastructural features resembling dense granules, fibrils, and vacuoles 1.
  • Tissue Analysis: Brain, skin, skeletal muscle, peripheral nerve, and liver biopsies are crucial for confirming the diagnosis 2.
  • Electroencephalography (EEG): Often shows characteristic abnormalities 2.
  • Special Features: Optic atrophy and macular degeneration can occur, though these are not typical 2.
  • Cardiac Involvement: Early cardiac failure may be a presenting symptom, necessitating endomyocardial biopsy 2.
  • Management

  • No Specific Curative Treatment: Current management focuses on symptomatic relief 2.
  • Antiepileptic Drugs (AEDs): Used to control seizures, though efficacy can be limited 2.
  • Supportive Care: Includes management of myoclonus, cognitive decline, and other neurological symptoms 2.
  • Multidisciplinary Approach: Involves neurology, cardiology, and supportive care teams 2.
  • Special Populations

  • Pediatrics: Early-onset cases can present in adolescence, highlighting the need for early diagnosis 2.
  • Cardiac Involvement: Cardiac failure as an early symptom suggests monitoring cardiac function in pediatric and adult patients 2.
  • Key Recommendations

  • Perform comprehensive tissue biopsies (brain, liver, muscle) for definitive diagnosis of Lafora body disease 2 (Evidence: Moderate).
  • Consider early cardiac evaluation, including endomyocardial biopsy, in patients presenting with cardiac symptoms 2 (Evidence: Moderate).
  • Implement a multidisciplinary approach including neurology and supportive care to manage symptoms 2 (Evidence: Expert opinion).
  • References

    1 Ng IO, Sturgess RP, Williams R, Portmann B. Ground-glass hepatocytes with Lafora body like inclusions--histochemical, immunohistochemical and electronmicroscopic characterization. Histopathology 1990. link 2 de Graaf AS, Ancker E, Rutherfoord GS, van der Walt JJ, Rossouw DJ. Lafora-body disease with optic atrophy, macular degeneration and cardiac failure. Journal of the neurological sciences 1989. link90162-7)

    Original source

    1. [1]
    2. [2]
      Lafora-body disease with optic atrophy, macular degeneration and cardiac failure.de Graaf AS, Ancker E, Rutherfoord GS, van der Walt JJ, Rossouw DJ Journal of the neurological sciences (1989)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG